Seven Eight Capital, LP Aurinia Pharmaceuticals Inc. Transaction History

Seven Eight Capital, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $43,395 - $68,527	-5,585 Reduced 34.94%	10,398 $80,000
Q2 2023 Aug 14, 2023	BUY	$8.96 - $11.69 $143,207 - $186,841	15,983 New	15,983 $154,000
Q3 2022 Nov 10, 2022	SELL	$6.66 - $12.39 $116,729 - $217,159	-17,527 Reduced 49.5%	17,881 $134,000
Q2 2022 Aug 04, 2022	SELL	$8.95 - $12.8 $697,160 - $997,056	-77,895 Reduced 68.75%	35,408 $356,000
Q1 2022 May 11, 2022	BUY	$10.05 - $22.48 $1.14 Million - $2.55 Million	113,303 New	113,303 $1.4 Million
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $5.14 Million - $9.55 Million	-288,840 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $2.66 Million - $5.74 Million	243,760 Added 540.73%	288,840 $6.39 Million
Q2 2021 Aug 13, 2021	BUY	$10.0 - $14.52 $450,800 - $654,561	45,080 New	45,080 $584,000
Q4 2020 Feb 09, 2021	SELL	$12.94 - $16.05 $471,455 - $584,765	-36,434 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $480,564 - $606,990	36,434 New	36,434 $537,000
Q2 2020 Aug 06, 2020	SELL	$14.12 - $18.33 $343,116 - $445,418	-24,300 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$11.34 - $21.46 $275,562 - $521,478	24,300 New	24,300 $353,000

209

58.2M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.